Latest on Pharmaceutical Industry


Zydus receives final approval from the USFDA for Entecavir Tablets

Zydus Cadila has received the final approval from the USFDA to market Entecavir Tablets in the strengths of 0.5 mg and 1 mg. The drug is used in the treatment of Hepatitis B Virus infection and will be produced at the..Read More...

Zosano Pharma announces outcome of end of phase 2 meetings with FDA

Zosano Pharma announces outcome of end of phase 2 meetings with FDA. Zosano Pharma - Received confirmation, a single efficacy study, our recently completed Zotrip trial, is sufficient to support an NDA filing for M207. ..Read More...



14th Laboratory Informatics Summit 2017

Philadelphia, Pennsylvania,


Biotech Outsourcing Strategies cmc 2017

Congress Center Basel (CCB),
Bio2Business Ltd.

Press Releases

Boston Biomedical Announces Unblinding of the Phase 3 Trial in Patients with Advanced Gastric/GEJ Cancer

Boston Biomedical Inc announced that the BRIGHTER Trial evaluating the efficacy and safety of napabucasin plus paclitaxel versus paclitaxel alone for patients with advanced gastricGEJ gastroesophageal junction cancer wil.. Read More...

MilliporeSigma adds Chemical Products to Reaxys' Chemistry Database

MilliporeSigma today announced a collaboration with Elsevier the information analytics company specializing in science and health to add its products into Reaxys Elsevier39s chemistry database Researchers and chemists.. Read More...

Suppliers of the Month

Product Launch



Latest Reports


Latest Projects


Expert Talk

Bayer Pharmaceuticals

Bayer Pharmaceuticals Christoph Huwe PhD CAAM is a Strategic Alliance Manager Therapeutics at Bayer AG Pharmaceuticals with a focus on the BayerEvotec Endometriosis BayerEvotec Kidney Diseases BayerOncoMed Oncology strategic alliances and the Tuberculosis Drug Accelerator consortium He is also a member of Bayers Alliance. Read More...
Christoph Huwe
Strategic Alliance Manager Therapeutics